NCT05101564View on ClinicalTrials.gov

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

PHASE2SuspendedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2026

Conditions
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer
Interventions
DRUG

Alpelisib

Alpelisib 300 mg

DRUG

Tamoxifen

Tamoxifen 20 mg

DRUG

Zotatifin

Zotatifin 0.10mg/kg (by weight)

DRUG

Fulvestrant

Fulvestrant 500 mg

Trial Locations (1)

94304

Stanford University, Stanford

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Effector Therapeutics

INDUSTRY

lead

Stanford University

OTHER